FluoroPharma Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Selling, General & Admin	1.69	2.47	3.42	2.92	2.73
Research & Development	0.51	0.72	1.75	1.31	1.42
Operating Expenses	2.2	3.19	5.17	4.23	4.15
Operating Income	-2.2	-3.19	-5.17	-4.23	-4.15
Interest Expense	-1.26	-0.79	-0.1	-0.05	-
Interest & Investment Income	-	-	0	0	0
Other Non Operating Income (Expenses)	2.3	0.64	1.35	0	-
EBT Excluding Unusual Items	-1.16	-3.34	-3.92	-4.28	-4.15
Gain (Loss) on Sale of Investments	-	-0	-0.07	-1.05	-
Gain (Loss) on Sale of Assets	-	-	-0.03	-	-0
Asset Writedown	-	-	-	-0.13	-
Other Unusual Items	-0.89	0.18	-0.1	-0.14	0.13
Pretax Income	-2.05	-3.16	-4.13	-5.61	-4.02
Net Income	-2.05	-3.16	-4.13	-5.61	-4.02
Preferred Dividends & Other Adjustments	0.52	0.57	0.56	1.68	0.17
Net Income to Common	-2.57	-3.74	-4.69	-7.28	-4.18
Shares Outstanding (Basic)	34	30	29	24	23
Shares Outstanding (Diluted)	34	30	29	24	23
Shares Change (YoY)	11.71%	4.88%	17.51%	7.65%	27.69%
EPS (Basic)	-0.08	-0.12	-0.16	-0.30	-0.18
EPS (Diluted)	-0.08	-0.12	-0.16	-0.30	-0.18
Free Cash Flow	-0.88	-2.68	-3.33	-3.34	-3.32
Free Cash Flow Per Share	-0.03	-0.09	-0.12	-0.14	-0.15
EBITDA	-2.16	-3.14	-5.13	-4.21	-4.13
D&A For EBITDA	0.04	0.05	0.04	0.02	0.02
EBIT	-2.2	-3.19	-5.17	-4.23	-4.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.